Carillon Tower Advisers’s Supernus Pharmaceuticals SUPN Stock Holding History

Carillon Tower Advisers’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$3.99M	Buy	158,677 +1,200	+0.8%	+$25.8K	0.02%	426
2020 Q3	$3.28M	Buy	157,477 +20,742	+15%	+$471K	0.04%	375
2020 Q2	$3.25M	Sell	136,735 -3,800	-3%	-$84K	0.03%	404
2020 Q1	$2.53M	Sell	140,535 -13,600	-9%	-$286K	0.02%	389
2019 Q4	$3.66M	Sell	154,135 -185,775	-55%	-$4.51M	0.02%	417
2019 Q3	$9.34M	Sell	339,910 -86,300	-20%	-$2.56M	0.07%	337
2019 Q2	$14.1M	Sell	426,210 -136,150	-24%	-$4.66M	0.1%	291
2019 Q1	$19.7M	Sell	562,360 -60,100	-10%	-$2.24M	0.14%	244
2018 Q4	$20.7M	Buy	622,460 +233,125	+60%	+$10M	0.18%	211
2018 Q3	$19.6M	Sell	389,335 -48,165	-11%	-$2.38M	0.14%	237
2018 Q2	$26.2M	Buy	437,500 +268,025	+158%	+$13.9M	0.21%	175
2018 Q1	$7.76M	Buy	+169,475	New	+$7.07M	0.06%	332

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

ACM

Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return

Carillon Tower Advisers's SUPN Position: Q4 2020 in Review

Carillon Tower Advisers increased its Supernus Pharmaceuticals (SUPN) stake by 0.76% in Q4 2020, buying an estimated $25.8K and bringing the position to 158,677 shares worth $3.99M. The position accounts for 0.02% of the portfolio, ranked #426.

Carillon Tower Advisers first reported a position in SUPN in Q1 2018 and has held it in 12 quarters since. The position peaked at $26.2M in Q2 2018. 225 funds tracked by Wall St. Rank hold SUPN as of Q4 2020.

Carillon Tower Advisers held 158,677 shares of Supernus Pharmaceuticals worth $3.99M as of Q4 2020.
Carillon Tower Advisers bought 1,200 Supernus Pharmaceuticals shares in Q4 2020, an estimated $25.8K.
Supernus Pharmaceuticals made up 0.02% of Carillon Tower Advisers's portfolio in Q4 2020, its #426 holding.
Carillon Tower Advisers first reported a position in Supernus Pharmaceuticals in Q1 2018 and has held it in 12 quarters since.
Carillon Tower Advisers's Supernus Pharmaceuticals position peaked at $26.2M in Q2 2018.
225 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.